Markers of angiogenesis and epidermal growth factor receptor signalling in patients with pancreatic and gastroesophageal junction cancer

Cancer Biomarkers

Volumn 7, Issue 3, 2010, Pages 141-151

  Rohrberg, Kristoffer Staal ^a   Skov, Birgit Guldhammer ^b   Lassen, Ulrik ^a   Christensen, Ib Jarle ^a   Høyer Hansen, Gunilla ^a   Buysschaert, Ian ^c,d   Pappot, Helle ^a  

^a FINSEN LABORATORY   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Angiogenesis; epidermal growth factor receptor; gastroesophageal junction cancer; pancreatic cancer

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; PLACENTAL GROWTH FACTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE RECEPTOR; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ADULT; ADVANCED CANCER; AGED; ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; DISEASE MARKER; ESOPHAGUS CANCER; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LOWER ESOPHAGUS SPHINCTER; MALE; METASTASIS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; STOMACH CANCER;

ADULT; AGED; CARCINOMA; EARLY DETECTION OF CANCER; ESOPHAGEAL NEOPLASMS; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 79954487333     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2010-0157     Document Type: Article

References (63)

1. C.E. Almasi, G. Hoyer-Hansen, I.J. Christensen and H. Pap-pot, Prognostic significance of urokinase plasminogen activa-tor receptor and its cleaved forms in blood from patients with non-small cell lung cancer, APMIS 117 (2009), 755-761.
2. S. Andersen, T. Donnem, S. Al-Saad, K. Al-Shibli, L.T. Busund and R.M. Bremnes, Angiogenic markers show high prognostic impact on survival in marginally operable non-small cell lung cancer patients treated with adjuvant radiother-apy, J Thorac Oncol 4 (2009), 463-471.
3. P. Angleton, W.L. Chandler and G. Schmer, Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1), Circulation 79 (1989), 101-106. (Pubitemid 19043680)
4. B.R. Binder, J. Mihaly and G.W. Prager, uPAR-uPA-PAI-1 in-teractions and signaling: a vascular biologist's view, Thromb-Haemost 97 (2007), 336-342. (Pubitemid 46437793)
5. Biomarkers Definitions Working Group, Biomarkers and sur-rogate endpoints: preferred definitions and conceptual frame-work, Clin Pharmacol Ther 69 (2001), 89-95.
6. M. Bloomston, A. Bhardwaj, E.C. Ellison and W.L. Frankel, Epidermal growth factor receptor expression in pancreatic car-cinoma using tissue microarray technique, Dig Surg 23 (2006), 74-79. (Pubitemid 44174844)
7. B. Bonnesen, H. Pappot, J. Holmstav and B.G. Skov, Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: Relation to prognosis, Lung Cancer (2009).
8. R.M. Bremnes, C Camps and R. Sirera, Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogen-esis and the cytokines VEGF and bFGF in tumours and blood, Lung Cancer 51 (2006), 143-158. (Pubitemid 43144358)
9. P. Buchler, H.A. Reber, M.W. Buchler, H. Friess and O.J. Hines, VEGF-RII influences the prognosis of pancreatic Cancer, Ann Surg 236 (2002), 738-749; discussion 749.
10. P. Carmeliet, Angiogenesis in life, disease and medicine, Nature 438 (2005), 932-936.
11. P. Carmeliet, VEGF as a key mediator of angiogenesis in cancer, Oncology 69(Suppl 3) (2005), 4-10. (Pubitemid 41680947)
12. P. Carmeliet and R.K. Jain, Angiogenesis in cancer and other diseases, Nature 407 (2000), 249-257.
13. E. Carrillo de Santa Pau, F.C. Arias, E. Caso Pelaez, G.M. Munoz Molina, I. Sanchez Hernandez, I. Muguruza Trueba, R. Moreno Balsalobre, S. Sacristan Lopez, A. Gomez Pinillos and M. del Val Toledo Lobo, Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer, Cancer 115 (2009), 1701-1712.
14. D. Cunningham and Y.J. Chua, East meets west in the treat-ment of gastric cancer. N Engl J Med357 (2007), 1863-1865. (Pubitemid 350044810)
15. K. Dano, N. Behrendt, G. Hoyer-Hansen, M. Johnsen, L.R. Lund, M. Ploug and J. Romer, Plasminogen activation and cancer, Thromb Haemost 93 (2005), 676-681. (Pubitemid 40485402)
16. S.E. DePrimo, C.L. Bello, J. Smeraglia, C.M. Baum, D. Spinella, B.I. Rini, M.D. Michaelson and R.J. Motzer, Cir-culating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins, JTransl Med 5:32 (2007), 32.
17. A. Dowlati, R. Gray, A.B. Sandler, J.H. Schiller and D.H. Johnson, Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncol-ogy Group Study, Clin Cancer Res 14 (2008), 1407-1412. (Pubitemid 351413922)
18. J. Drevs, U. Zirrgiebel, C.I. Schmidt-Gersbach, K. Mross, M. Medinger, L. Lee, J. Pinheiro, J. Wood, A.L. Thomas, C Unger, A. Henry, W.P. Steward, D. Laurent, D. Lebwohl, M. Dugan and D. Marme, Soluble markers for the assessment ofbiological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials, Ann Oncol 16 (2005), 558-565. (Pubitemid 40613321)
19. A. Driessen, W. Landuyt, S. Pastorekova, J. Moons, L. Goethals, K. Haustermans, P. Nafteux, F. Penninckx, K. Geboes, T. Lerut and N. Ectors, Expression of carbon-ic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor progno-sis in esophageal and gastric adenocarcinomas, Ann Surg 243 (2006), 334-340. (Pubitemid 43327764)
20. J. M. Ebos, G. Bocci, S. Man, P.E. Thorpe, D.J. Hicklin, D. Zhou, X. Jia and R.S. Kerbel, A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma, Mol Cancer Res 2 (2004), 315-326. (Pubitemid 39025294)
21. J.M. Ebos, C.R. Lee, E. Bogdanovic, J. Alami, P. Van Slyke, G. Francia, P. Xu, A.J. Mutsaers, D.J. Dumont and R.S. Ker-bel, Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth, Cancer Res 68 (2008), 521-529. (Pubitemid 351380080)
22. C Festuccia, A. Angelucci, G.L. Gravina, L. Biordi, D. Mil-limaggi, P. Muzi, C Vicentini and M. Bologna, Epidermal growth factor modulates prostate cancer cell invasiveness reg-ulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination, Thromb Haemost 93 (2005), 964-975. (Pubitemid 40691556)
23. C Fischer, B. Jonckx, M. Mazzone, S. Zacchigna, S. Loges, L. Pattarini, E. Chorianopoulos, L. Liesenborghs, M. Koch, M. De Mol, M. Autiero, S. Wyns, S. Plaisance, L. Moons, N. van Rooijen, M. Giacca, J.M. Stassen, M. Dewerchin, D. Collen and P. Carmeliet, Anti-PlGF inhibits growth of VEGF(R)-inhibitor- resistant tumors without affecting healthy vessels, Cell 131 (2007), 463-475. (Pubitemid 350007692)
24. C Fischer, M. Mazzone, B. Jonckx and P. Carmeliet. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 8 (2008), 942-956.
25. I. Fukuda, M. Yamakado and H. Kiyose, Influence of smoking on serum carcinoembryonic antigen levels in subjects who underwent multiphasic health testing and services, JMed Syst 22 (1998), 89-93. (Pubitemid 28183525)
26. G. Galizia, E. Lieto, M. Orditura, P. Castellano, A.L. Mura, V. Imperatore, M. Pinto, A. Zamboli, F. De Vita and F. Fer-raraccio, Epidermal growth factor receptor (EGFR) expres-sion is associated with a worse prognosis in gastric cancer patients undergoing curative surgery, World J Surg 31 (2007), 1458-1468. (Pubitemid 46945355)
27. S. Ghosh, C.A. Sullivan, M.P. Zerkowski, A.M. Molinaro, D.L. Rimm, R.L. Camp and G.G. Chung, High levels of vas-cular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer, Hum Pathol 39 (2008), 1835-1843.
28. L. Gibault, J.P. Metges, V. Conan-Charlet, P. Lozac'h, M. Robaszkiewicz, C Bessaguet, N. Lagarde and A. Volant, Dif-fuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer, Br J Cancer 93 (2005), 107-115. (Pubitemid 41076258)
29. F.J. Gonzalez, L. Vicioso, M. Alvarez, I. Sevilla, E. Marques, E. Gallego, L. Alonso, A. Matilla and E. Alba, Association between VEGF expression in tumour-associated macrophages and elevated serum VEGF levels in primary colorectal cancer patients, Cancer Biomarkers 3 (2007), 325-333. (Pubitemid 350187033)
30. E.A. Griffiths, S.A. Pritchard, S.M. McGrath, H.R. Valentine, P.M. Price, I.M. Welch and C.M. West, Increasing expres-sion of hypoxia-inducible proteins inthe Barrett's metaplasia-dysplasia-adenocarcinoma sequence, Br J Cancer 96 (2007), 1377-1383. (Pubitemid 46685799)
31. M.L. Hetland, I.J. Christensen, T. Lottenburger, J.S. Johansen, M.N. Svendsen, K. Horslev-Petersen, L. Nielsen and H.J. Nielsen, Circulating VEGF as a biological marker in patients with rheumatoid arthritis? Preanalytical and biological vari-ability in healthy persons and in patients, Dis Markers 24 (2008), 1-10. (Pubitemid 350174565)
32. M.C. Ho, C.N. Chen, H. Lee, F.J. Hsieh, C.T. Shun, C.L. Chang, Y.T. Lai and P.H. Lee, Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma, Cancer Lett 250 (2007), 237-249. (Pubitemid 46529444)
33. M.Y Homs, E.E. Voest and P.D. Siersema, Emerging drugs for esophageal cancer, Expert Opin Emerg Drugs 14 (2009), 329-339.
34. G. Hudelist, W.J. Kostler, D. Gschwantler-Kaulich, K. Czer-wenka, E. Kubista, R. Muller, S. Helmy, M. Manavi, C.C. Zielinski and C.F. Singer, Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer, Eur J Cancer 42 (2006), 186-192. (Pubitemid 43083488)
35. M. Jo, K.S. Thomas, S. Takimoto, A. Gaultier, E.H. Hsieh, R.D. Lester and S.L. Gonias, Urokinase receptor primes cells to proliferate in response to epidermal growth factor, Onco-gene 26 (2007), 2585-2594. (Pubitemid 46632010)
36. H. Joensuu, A. Anttonen, M. Eriksson, R. Makitaro, H. Alfthan, V. Kinnula and S. Leppa, Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer, Cancer Res 62 (2002), 5210-5217. (Pubitemid 35024592)
37. M.A. Kim, H.S. Lee, H.E. Lee, Y.K. Jeon, H.K. Yang and W.H. Kim, EGFR in gastric carcinomas: prognostic signifi-cance of protein overexpression and high gene copy number, Histopathology 52 (2008), 738-746. (Pubitemid 351600058)
38. R.S. La, S. Uccella, G. Finzi, L. Albarello, F. Sessa and C Capella, Localization of vascular endothelial growth fac-tor and its receptors in digestive endocrine tumors: correla-tion with microvessel density and clinicopathologic features, Hum Pathol 34 (2003), 18-27. (Pubitemid 36160017)
39. Y Lemos-Gonzalez, F.J. Rodriguez-Berrocal, O.J. Cordero, C Gomez and M. Paez de la Cadena. Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma, Br J Cancer 96 (2007), 1569-1578. (Pubitemid 46762963)
40. E. Lieto, F. Ferraraccio, M. Orditura, P. Castellano, A.L. Mura, M. Pinto, A. Zamboli, F. De Vita and G. Galizia, Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients, Ann Surg Oncol 15 (2008), 69-79.
41. D. Liu, J. Aguirre Ghiso, Y Estrada and L. Ossowski. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma, Cancer Cell 1 (2002), 445-457. (Pubitemid 41039125)
42. M.P. Look, W.L. van Putten, M.J. Duffy, N. Harbeck, I.J. Christensen, C Thomssen, R. Kates, F. Spyratos, M. Ferno, S. Eppenberger-Castori, C.G. Sweep, K. Ulm, J.P. Peyrat, P.M. Martin, H. Magdelenat, N. Brunner, C Duggan, B.W. Lis-boa, P.O. Bendahl, V. Quillien, A. Daver, G. Ricolleau, M.E. Meijer-van Gelder, P. Manders, W.E. Fiets, M.A. Blanken-stein, P. Broet, S. Romain, G. Daxenbichler, G. Windbichler, T. Cufer, S. Borstnar, W. Kueng, L.V. Beex, J.G. Klijn, N. O'Higgins, U. Eppenberger, F. Janicke, M. Schmitt and J.A. Foekens, Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients, JNatl Cancer Inst 94 (2002), 116-128. (Pubitemid 34121291)
43. R. Masood, J. Cai, T. Zheng, D.L. Smith, D.R. Hinton and P.S. Gill, Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors, Blood 98 (2001), 1904-1913.
44. I.I.S. Modrau, L.L.H. Iversen and O.O. Thorlacius-Ussing. Hemostatic Alterations in Patients with Benign and Malig-nant Colorectal Disease During Major Abdominal Surgery, Thrombosis Research 104 (2001), 309-315. (Pubitemid 33152951)
45. H.J. Nielsen, I.J. Christensen, S. Sorensen, F. Moesgaard and N. Brunner, Preoperative plasma plasminogen activator in-hibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group, Ann Surg Oncol 7 (2000), 617-623.
46. N. Normanno, C Bianco, L. Strizzi, M. Mancino, M.R. Maiel-lo, L.A. De, F. Caponigro and D.S. Salomon, The ErbB re-ceptors and their ligands in cancer: an overview, Curr Drug Targets 6 (2005), 243-257. (Pubitemid 40667793)
47. E.M. O'Reilly, Pancreatic adenocarcinoma: new strategies for success, Gastrointest Cancer Res 3 (2009), S1 1-S15.
48. F.J. Olson, T Thurison, M. Ryndel, G. Hoyer-Hansen and B. Fagerberg, Soluble urokinase-type plasminogen activator receptor forms in plasma as markers of atherosclerotic plaque vulnerability, Clin Biochem (2009).
49. M. Perez-Torres, B.L. Valle, N.J. Maihle, L. Negron-Vega, R. Nieves-Alicea and E.M. Cora, Shedding ofepidermal growth factor receptor is a regulated process that occurs with overex-pression in malignant cells, Exp Cell Res 314 (2008), 2907-2918.
50. T Piironen, A. Haese, H. Huland, T Steuber, I.J. Christensen, N. Brunner, K. Dano, G. Hoyer-Hansen and H. Lilja, Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum, Clin Chem 52 (2006), 838-844. (Pubitemid 43673262)
51. T Piironen, B. Laursen, J. Pass, K. List, H. Gardsvoll, M. Ploug, K. Dano and G. Hoyer-Hansen, Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor, Clin Chem 50 (2004), 2059-2068. (Pubitemid 39425843)
52. R.T Poon, S.T. Fan and J. Wong, Clinical implications of circulating angiogenic factors in cancer patients, J Clin Oncol 19(2001), 1207-1225. (Pubitemid 32176299)
53. M. Presta, P. Dell'Era, S. Mitola, E. Moroni, R. Ronca and M. Rusnati, Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis, Cytokine Growth Factor Rev 16 (2005), 159-178. (Pubitemid 40616114)
54. M.G. Rasch, I.K. Lund, C.E. Almasi and G. Hoyer-Hansen, Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer, Front Biosci 13 (2008), 6752-6762.
55. D. Ribatti, The discovery of the placental growth factor and its role in angiogenesis: a historical review, Angiogenesis 11 (2008), 215-221.
56. Y Seo, H. Baba, T Fukuda, M. Takashima and K. Sugimachi, High expression of vascular endothelial growth factor is asso-ciated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma, Cancer 88 (2000), 2239-2245. (Pubitemid 30247122)
57. H.M. Shantha Kumara, J.C. Cabot, A. Hoffman, M. Luchte-feld, M.F. Kalady, N. Hyman, D. Feingold, R. Baxter and R.L. Whelan, Minimally invasive colon resection for malig-nant colonic conditions is associated with a transient early in-crease in plasma sVEGFR1 and a decrease in sVEGFR2 levels after surgery, Surg Endosc (2009).
58. M.N. Svendsen, J. Lykke, K. Werther, I.J. Christensen and H.J. Nielsen, Concentrations of VEGF and VEGFR1 inpaired tumor arteries and veins in patients with rectal cancer, Oncol Res 14 (2004), 611-615. (Pubitemid 40178962)
59. Y.W. Tien, K.J. Chang, Y.F. Chiu, K.W. Huang and P.H. Lee, Comparison of angiogenic factor levels in tumor drainage and peripheral venous blood from colorectal cancer patients, Ann Surg Oncol 13 (2006), 1357-1363.
60. N.W. Wilkinson, J.D. Black, E. Roukhadze, D. Driscoll, S. Smiley, H. Hoshi, J. Geradts, M. Javle and M. Brattain, Epi-dermal growth factor receptor expression correlates with his-tologic grade in resected esophageal adenocarcinoma, J Gas-trointest Surg 8 (2004), 448-453. (Pubitemid 38561209)
61. C.G. Willett, D.G. Duda, E. di Tomaso, Y Boucher, M. An-cukiewicz, D.V. Sahani, J. Lahdenranta, D.C. Chung, A.J. Fis-chman, G.Y Lauwers, P. Shellito, B.G. Czito, T.Z. Wong, E. Paulson, M. Poleski, Z. Vujaskovic, R. Bentley, H.X. Chen, J.W. Clark and R.K. Jain, Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study, J Clin Oncol 27 (2009), 3020-3026.
62. M.G. Zampino, E. Magni, L. Santoro, L. Zorzino, P. Dell'Orto, A. Sonzogni, N. Fazio, L. Monfardini, A. Chiappa, R. Biffi and F. de Braud, Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib? Cancer Chemother Pharmacol 63 (2008), 139-148.
63. Z.S. Zhao, YY Wang, Z.Y Ye and H.Q. Tao, Prognostic Value of Tumor-Related Molecular Expression in Gastric Carcino-ma, Pathol Oncol Res (2009).